IO Frontiers World 2019


Stanley Frankel

Dr Stanley Frankel

Corporate Vice President, Head Immuno-Oncology R&D, Celgene

Dr. Frankel is Corporate Vice President, Head of Immuno-oncology, Clinical Research and Development at Celgene. His current research focus includes checkpoint inhibitors and cellular therapies.


Through 2014 he served as  Executive Director, Medical Sciences; Early Development, Oncology Therapeutic Area Head at Amgen. Among his primary responsibilities at Amgen were the clinical development of bispecific T cell engaging antibody constructs (BiTE®s) inclucing blinatumomab, immune-oncology agents, antibody drug conjugates, and small molecules directed at anti-apoptotic proteins. He joined Amgen following the acquisition of Micromet where he served as Vice President, Clinical Develoment.


Prior experience includes roles as Clinical Director and Clinical Science Leader at Hoffman-LaRoche; Executive Director for US External Scientific Affairs and Senior Director, Clinical Research at Merck. Dr. Frankel chaired the  Zolinza Product Development Team and led the clinical efforts for the successful approval of Zolinza in 2006. From 2001-2004, he was Director, Medical Operations, at Genta, Inc working on Genasense.


Prior to joining Genta, Dr. Frankel was Clinical Associate Professor of Medicine at the University of Maryland in Baltimore Greenebaum Cancer Center. He was previously on  the faculty at Roswell Park Cancer Institute in Buffalo, NY and the Lombardi Cancer Center at Georgetown University.


Dr. Frankel received his B.A. from Harvard College and his M.D. from Northwestern University. He received his post-graduate training at Mount Sinai Hospital in New York, and Memorial Sloan-Kettering Cancer Center where he was Chief Fellow.


In addition to his contributions to the approval of Blincyto and Zolinza, Dr. Frankel worked as an academic investigator on the development of 11 other approved oncology drugs including Vesanoid and Trisenox for acute promyelocytic leukemia, Rituxan, Zevalin, Bexxar for CD20 expressing malignancies, Neulasta, Kepivance, Mylotarg, and Gleevec. Dr. Frankel has internationally recognized clinical expertise in the treatment of hematologic malignancies including ALL and lymphoma.


Dr. Frankel is a Diplomate of the  American Board of Internal Medicine with subspecialty credentials in Hematology and Medical Oncology. He is also an Adjunct Associate Professor of Medicine at Columbia College of Physicians and Surgeons.

He is a Fellow of the American College of Physicians. He is a member of  AACR, ASBMT, ASCO, ASH, EHA, and ESMO. He has authored more than 80 peer-reviewed scientific papers.  

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy